SK biopharmaceuticals KRX:326030KOSPI
에스케이바이오팜 · Korean news coverage and regulatory filings, organized.
In Q2 2026, SK biopharmaceuticals reported revenue of ₩247bn, up 40.3% year on year, and operating profit of ₩97.1bn. SK biopharmaceuticals (에스케이바이오팜) appeared in 5 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 9 articles. The most common catalyst was clinical & approvals (4). It was most often mentioned alongside 글로벌테크놀로지, ST Pharm and OliX Pharmaceuticals.
Filing signals Profit +50% Revenue +30% Revenue & profit growth Op. margin 20%+ Screener
SK biopharmaceuticals quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩247bn | +40.3% | ₩97.1bn margin 39.2% | ₩85.1bn |
| Q1 2026 | ₩228bn | +57.8% | ₩89.8bn margin 39.4% | ₩103bn |
| Q4 2025 derived | ₩194bn | +19.2% | ₩46.3bn margin 23.8% | ₩133bn |
| Q3 2025 | ₩192bn | +40.4% | ₩70.1bn margin 36.6% | ₩71.4bn |
| Q2 2025 | ₩176bn | +31.6% | ₩61.9bn margin 35.1% | ₩29.5bn |
| Q1 2025 | ₩144bn | +26.7% | ₩25.7bn margin 17.8% | ₩19.6bn |
| Q4 2024 derived | ₩163bn | +28.6% | ₩40.7bn margin 24.9% | ₩186bn |
| Q3 2024 | ₩137bn | +51.2% | ₩19.3bn margin 14.2% | ₩6.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
SK biopharmaceuticals top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest SK biopharmaceuticals news Korean headlines
-
SK바이오팜, 엑스코프리 성장에 3Q 호실적 전망…목표가 15.5만원 유지-DS
2 more on this story · 2 outlets
- SK바이오팜, 엑스코프리 성장에 3Q 호실적 전망…목표가 15.5만원 유지-DS이데일리증권 · Oct 21 07:58
- SK바이오팜, 엑스코프리 성장에 3Q 호실적 전망…목표가 15.5만원 유지-DS이데일리 · Oct 21 08:00